Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ: CPRX )

20.87 -0.33 (-1.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 829,626
Open 21.07
Bid (Size) 20.40 (10)
Ask (Size) 21.19 (10)
Prev. Close 21.20
Today's Range 20.68 - 21.25
52wk Range 14.47 - 24.49
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a CANSLIM stock.
A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for Growth Investing Strategies? 
Via Chartmill
Looking for growth without the hefty price tag? Consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced... 
Via Chartmill

Performance

YTD
-3.02%
-3.02%
1 Month
-8.30%
-8.30%
3 Month
-5.01%
-5.01%
6 Month
+7.25%
+7.25%
1 Year
+28.83%
+28.83%

More News

Read More
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing?
Via Chartmill
Earnings Scheduled For February 26, 2025
Via Benzinga
Why NASDAQ:CPRX qualifies as a high growth stock.
Via Chartmill
Unlocking the Growth Potential of NASDAQ:CPRX.
Via Chartmill
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
Via The Motley Fool
Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Investors should take note of NASDAQ:CPRX, a growth stock that remains attractively priced.
Via Chartmill
Exploring NASDAQ:CPRX's high growth characteristics.
Via Chartmill
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock
Via Benzinga
Unlocking the Growth Potential of NASDAQ:CPRX.
Via Chartmill
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
NASDAQ:CPRX: good value for what you're paying.
Via Chartmill
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Why NASDAQ:CPRX qualifies as a high growth stock.
Via Chartmill
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
Via Chartmill
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
While growth is established for NASDAQ:CPRX, the stock's valuation remains reasonable.
Via Chartmill
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.